Tong-Chuan (T.-C.) He, MD, PhD
Associate Professor of Surgery
Orthopaedic Oncology/Research
Director,
Molecular Oncology
Laboratory
Associate Investigator, The University of
Chicago Cancer Research Center
Committee on Cancer Biology
Committee on Genetics
Committee on Molecular Medicine
Committee on
Cell Physiology
MD: Chongqing
Medical University, China
PhD: The Pennsylvania State University, University Park, PA
Postdoctoral: HHMI and Johns Hopkins Oncology Center.
Memberships: AACR, AAAA, ORS, ASM, and ASBMR
Dr.
Tong-Chuan He received his M.D. and M.S. degree in Biochemistry
from Chongqing Medical University, Chongqing,
China. Dr. He received his Ph.D. in Molecular and Cell
Biology from the Department of Biochemistry and Molecular
Biology of The Pennsylvania State University, University Park, PA. Dr. He pursued his postdoctoral
training under the guidance of two internationally renowned
scientists Drs. Bert Vogelstein and Kenneth Kinzler at the
Howard Hughes Medical Institute and Johns Hopkins Medical
Institution, Baltimore, MD. During his tenure, Dr. He made
significant contributions in two areas. First, he developed an
innovative technology for generating recombinant adenoviral
vectors for gene delivery (He et al. PNAS 95:2509-2514).
This patented technology is now being used by more than 3,000
research laboratories throughout the world. Second, Dr. He was
the first to identify the molecular targets that may function as
the critical mediators of the oncogenic activity of the Wnt/β-catenin
signaling pathway in human cancers (He et al. Science
281:1509-1512; and He et al. Cell 99:335-345).
These fundamental findings have been cited nearly 4,000 times
since their publications.
The long-term objective of his research
at The University of Chicago is two-fold:
1) to understand the molecular bases of bone and musculoskeletal
diseases, especially bone and soft tissue tumors; and 2) to
develop innovative therapeutic and/or preventive strategies for
these disorders by translating basic findings from bench work
into applications in pre-clinical and/or clinical settings.
In addition to his
primary appointment, Dr. He serves on the
Institutional Biosafety Committee of The University of Chicago.
To
read the recent publications from Dr. He Lab,
click here.
For more information about Dr. He laboratory, please visit
his lab homepage at:
www.boneandcancer.org
last update:
01/25/2010 |
